BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1064 related articles for article (PubMed ID: 16128910)

  • 1. An antithrombotic agent, NQ301, inhibits thromboxane A2 receptor and synthase activity in rabbit platelets.
    Jin YR; Cho MR; Lee KS; Lee JJ; Lim Y; Han XH; Oh KW; Hong JT; Yoo HS; Yun YP
    Basic Clin Pharmacol Toxicol; 2005 Sep; 97(3):162-7. PubMed ID: 16128910
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiplatelet activity of J78 (2-Chloro-3-[2'-bromo, 4'-fluoro-phenyl]-amino-8-hydroxy-1,4-naphthoquinone), an antithrombotic agent, is mediated by thromboxane (TX) A2 receptor blockade with TXA2 synthase inhibition and suppression of cytosolic Ca2+ mobilization.
    Jin YR; Cho MR; Ryu CK; Chung JH; Yuk DY; Hong JT; Lee KS; Lee JJ; Lee MY; Lim Y; Yun YP
    J Pharmacol Exp Ther; 2005 Jan; 312(1):214-9. PubMed ID: 15328379
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiplatelet activity of carnosol is mediated by the inhibition of TXA2 receptor and cytosolic calcium mobilization.
    Lee JJ; Jin YR; Lim Y; Hong JT; Kim TJ; Chung JH; Yun YP
    Vascul Pharmacol; 2006 Sep; 45(3):148-53. PubMed ID: 16916624
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The protective effects of paclitaxel on platelet aggregation through the inhibition of thromboxane A2 synthase.
    Lee JJ; Yu JY; Lee JH; Zhang WY; Kim TJ; Myung CS; Yun YP
    Arch Pharm Res; 2010 Mar; 33(3):387-94. PubMed ID: 20361303
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiplatelet effect of NQ12: a possible mechanism through the arachidonic acid cascade.
    Jin YR; Han XH; Lee JJ; Lim Y; Kim TJ; Yoo HS; Hong JT; Lee CK; Yun YP
    J Pharmacol Sci; 2007 Oct; 105(2):193-200. PubMed ID: 17951980
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanism for antiplatelet effect of onion: AA release inhibition, thromboxane A(2)synthase inhibition and TXA(2)/PGH(2)receptor blockade.
    Moon CH; Jung YS; Kim MH; Lee SH; Baik EJ; Park SW
    Prostaglandins Leukot Essent Fatty Acids; 2000 May; 62(5):277-83. PubMed ID: 10883058
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiplatelet activity of epigallocatechin gallate is mediated by the inhibition of PLCgamma2 phosphorylation, elevation of PGD2 production, and maintaining calcium-ATPase activity.
    Jin YR; Im JH; Park ES; Cho MR; Han XH; Lee JJ; Lim Y; Kim TJ; Yun YP
    J Cardiovasc Pharmacol; 2008 Jan; 51(1):45-54. PubMed ID: 18209568
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiplatelet effect of green tea catechins: a possible mechanism through arachidonic acid pathway.
    Son DJ; Cho MR; Jin YR; Kim SY; Park YH; Lee SH; Akiba S; Sato T; Yun YP
    Prostaglandins Leukot Essent Fatty Acids; 2004 Jul; 71(1):25-31. PubMed ID: 15172681
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thromboxane A2 synthase inhibition and thromboxane A2 receptor blockade by 2-[(4-cyanophenyl)amino]-3-chloro-1,4-naphthalenedione (NQ-Y15) in rat platelets.
    Chang TS; Kim HM; Lee KS; Khil LY; Mar WC; Ryu CK; Moon CK
    Biochem Pharmacol; 1997 Jul; 54(2):259-68. PubMed ID: 9271330
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thromboxane synthase inhibitors suppress more effectively the aggregation of thromboxane receptor-desensitized than that of normal platelets: role of adenylylcyclase up-regulation.
    Vezza R; Nenci GG; Gresele P
    J Pharmacol Exp Ther; 1995 Dec; 275(3):1497-505. PubMed ID: 8531121
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 2-(2-Br-phenyl)-8-methoxy-benzoxazinone (HPW-RX2), a direct thrombin inhibitor with a suppressive effect on thromboxane formation in platelets.
    Wu CC; Wang TW; Wang WY; Hsieh PW; Wu YC
    Eur J Pharmacol; 2005 Dec; 527(1-3):37-43. PubMed ID: 16313903
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of N,N'-bis(3-picolyl)-4-methoxy-isophtalamide (picotamide) as a dual thromboxane synthase inhibitor/thromboxane A2 receptor antagonist in human platelets.
    Gresele P; Deckmyn H; Arnout J; Nenci GG; Vermylen J
    Thromb Haemost; 1989 Jun; 61(3):479-84. PubMed ID: 2552606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiplatelet activity of carnosic acid, a phenolic diterpene from Rosmarinus officinalis.
    Lee JJ; Jin YR; Lee JH; Yu JY; Han XH; Oh KW; Hong JT; Kim TJ; Yun YP
    Planta Med; 2007 Feb; 73(2):121-7. PubMed ID: 17410649
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiplatelet effect of a new inhibitor of thromboxane synthase and thromboxane A2 receptors.
    Tubaro E; Belogi L; Mezzadri CM
    Arzneimittelforschung; 1996 Jan; 46(1):35-41. PubMed ID: 8821515
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological characterization of FCE 27262, a combined thromboxane synthase inhibitor and PGH2/TXA2 receptor antagonist.
    Vaghi F; Colombo M; Pierucci L; Volpi D; Dho L; Ukmar G; Rosa B; Salvati P
    Drugs Exp Clin Res; 1993; 19(6):249-60. PubMed ID: 8013268
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-platelet activity of KR-32560, a novel sodium/hydrogen exchanger-1 inhibitor.
    Lee KS; Jin YR; Lee JJ; Lim Y; Son DJ; Lee CK; Yi KY; Yoo SE; Shin HS; Yun YP
    Pharmacol Res; 2006 Mar; 53(3):265-70. PubMed ID: 16420980
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The antiplatelet activity of Geiji-Bokryung-Hwan, Korean traditional formulation, is mediated through inhibition of phospholipase C and inhibition of TxB(2) synthetase activity.
    Park WH; Kim KS; Kim KH; Kim DS; Kim CH
    Int Immunopharmacol; 2003 Jul; 3(7):971-8. PubMed ID: 12810354
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiplatelet activity of hesperetin, a bioflavonoid, is mainly mediated by inhibition of PLC-gamma2 phosphorylation and cyclooxygenase-1 activity.
    Jin YR; Han XH; Zhang YH; Lee JJ; Lim Y; Chung JH; Yun YP
    Atherosclerosis; 2007 Sep; 194(1):144-52. PubMed ID: 17092506
    [TBL] [Abstract][Full Text] [Related]  

  • 19. R 68 070: thromboxane A2 synthetase inhibition and thromboxane A2/prostaglandin endoperoxide receptor blockade combined in one molecule--I. Biochemical profile in vitro.
    De Clerck F; Beetens J; de Chaffoy de Courcelles D; Freyne E; Janssen PA
    Thromb Haemost; 1989 Feb; 61(1):35-42. PubMed ID: 2546278
    [TBL] [Abstract][Full Text] [Related]  

  • 20. "In vitro" and "ex vivo" effects of picotamide, a combined thromboxane A2-synthase inhibitor and -receptor antagonist, on human platelets.
    Berrettini M; De Cunto M; Parise P; Grasselli S; Nenci GG
    Eur J Clin Pharmacol; 1990; 39(5):495-500. PubMed ID: 1963845
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 54.